Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
EUCTR |
Last refreshed on:
|
19 March 2012 |
Main ID: |
EUCTR2008-008753-33-PT |
Date of registration:
|
05/05/2009 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
A Randomized, Double-Blind, Placebo- and Active-Controlled Study of
Carisbamate in the Treatment of Neuropathic Pain in Diabetic Peripheral
Neuropathy Followed by a Blinded Extension Phase
|
Scientific title:
|
A Randomized, Double-Blind, Placebo- and Active-Controlled Study of
Carisbamate in the Treatment of Neuropathic Pain in Diabetic Peripheral
Neuropathy Followed by a Blinded Extension Phase |
Date of first enrolment:
|
31/07/2009 |
Target sample size:
|
440 |
Recruitment status: |
Not Recruiting |
URL:
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-008753-33 |
Study type:
|
Interventional clinical trial of medicinal product |
Study design:
|
Controlled: yes
Randomised: yes
Open: no
Single blind: no
Double blind: yes
Parallel group: yes
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: yes
Placebo: yes
Other: no
|
Phase:
|
|
|
Countries of recruitment
|
France
|
Netherlands
|
Portugal
|
Spain
| | | | |
Contacts
|
Name:
|
|
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
|
|
Name:
|
|
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
|
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: • Men or women between 18 and 75 years of age, inclusive • Have diabetes mellitus (Type 1 or Type 2) • Subjects must meet the following criteria at the end of the baseline period to be randomly assigned into the double-blind treatment phase of the study: – Documented daily average DPN pain assessments (ie, evening ratings for pain over the past 24 hours) for at least 5 days in the baseline period – Mean Daily Average DPN Pain score of at least 4 on an 11-point scale during the baseline period • Have symptoms of diabetes-related painful peripheral neuropathy in the distal extremities for at least 6 months prior to study entry. The pain symptoms must be attributable to DPN confirmed by history and findings on neurologic examination. • Experienced lower extremity pain due to diabetic neuropathy on a nearly daily basis for the previous 3 months • Have hemoglobin A1c (HbA1c) levels =11% • Have a stable diabetic treatment regimen, including oral hypoglycemics, insulin, or diet for 3 months before screening RWJ-333369 (carisbamate): Clinical Protocol CARISNPP2003 FINAL – 21 January 2009 40 • Willing to discontinue treatment for chronic pain with AEDs (including gabapentin or pregabalin), opioids or opioid-containing analgesics, or SNRIs or tricyclic antidepressants for any indication. Willing to discontinue other prohibited medications (see Attachment 1). • Women must be: – postmenopausal (for at least 2 years) – surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal ligation, or otherwise be incapable of pregnancy) – abstinent (at the discretion of the investigator/per local regulations) – if sexually active, be practicing a highly effective method of birth control (eg, prescription oral contraceptives provided the subject is receiving a dosage that has been adjusted for concomitant use of any drug known to significantly affect the metabolism of hormonal contraceptives, contraceptive injections, contraceptive patch, intrauterine device, double-barrier method [eg, condoms, diaphragm, or cervical cap, with spermicidal foam, cream, or gel], male partner sterilization) as local regulations permit before entry, and must agree to continue to use the same method of contraception throughout the study. • Women of childbearing potential must have a negative urine pregnancy test at screening; and at the time of random assignment to treatment on Day 1. • Negative urine drug screen and blood alcohol test at screening • Negative for hepatitis B infection, according to the interpretation of hepatitis B serology test results • Negative for anti-hepatitis C virus antibody (anti-HCV) • Able and willing to read and comprehend written instructions, to complete study questionnaires, and to make daily phone calls to the IVRS to report daily DPN pain and sleep assessments • Willing/able to adhere to the prohibitions and restrictions specified in this protocol • Subjects must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study. • To participate in the optional pharmacogenomic component of this study, subjects must have signed the informed consent form for pharmacogenomic research indicating willingness to participate in the pharmacogenomic component of the study (where local regulations permit). Refusal to give consent for this component does not exclude a subject from participation in the clinical study. Are the trial subjects
Exclusion criteria: • History of poor response to 3 or more classes of medications for DPN. Note: Poor response is defined as treatment with medications in the following classes of therapy for greater than 1 month at clinically accepted therapeutic dosages without at least moderate improvement in the judgment of the investigator: – AEDs – tricyclic antidepressants – SNRIs – opioid analgesics – lidocaine patch • Known allergies, hypersensitivity, or intolerance to carisbamate or its excipients (refer to Section 14.1, Physical Description of Study Drug(s) • History of allergic reaction or other clinically significant or treatment-limiting side effect due to pregabalin • Currently taking Coumadin® (warfarin) • Use of disallowed therapies: see Attachment 1 • Prior neurolytic treatment (destruction of nerves by the application of chemicals, heat, or cold), neurosurgery, intrathecal pumps, or spinal cord stimulators for their DPN pain • Use of herbal topical creams or ointments for pain relief within 48 hours, capsaicin within 6 months, or systemic corticosteroids within 3 months before the baseline period • Dermatologic or vascular disease in the limbs affected by the neuralgia that may interfere with assessment, including a diabetic ulcer or any toe or limb amputation • History of a chronic pain condition (eg, joint osteoarthritis or low back pain) that is more severe than their DPN or that requires daily analgesic treatment • Hospitalized within the past 1 month for episodes of hypoglycemia/hyperglycemia • Clinical diagnosis of human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS) or any immune deficiency • History of progressive or neurologic disorders (eg, multiple sclerosis, amyotrophic lateral sclerosis) that may interfere with completion of the study or interpretation of study results • Medically unstable on the basis of clinical laboratory tests performed at screening. If the results of the serum chemistry panel [including liver enzymes, other specific tests], hematology, or urinalysis are outside the normal reference ranges, the subject may be included only if the investigator judges the abnormalities or deviations from normal to be not clinically significant or to be appropriate and reasonable for the population under study. This determination must be recorded in the subject's source documents and initialed by the investigator. The values must be contained within 1.5 times the ULN for ALT and AST, and must be below the ULN for total bilirubin. RWJ-333369 (carisbamate): Clinical Protocol CARISNPP2003 FINAL – 21 January 2009 42 • History of liver impairment or renal insufficiency; significant or unstable cardiac, vascular, pulmonary, endocrine, rheumatologic or gastrointestinal conditions including moderate to severe gastroparesis, or an anticipated need for surgery • Glomerular filtration rate (GFR) less than 50 mL/min as estimated by the Modification of Diet in Renal Disease Study Equation: GFR = 175 x (standardized serum creatinine)-1.154 x (age)-0.203 x 0.742 (if subject is female) or x 1.212 (if subject is black) • Known malignancy or history of malignancy within the past 5 years with the exception of basal cell carcinoma that has been treated and is no longer present • History of or suggested clinical diagnosis of schizophrenia, bipolar disorder, dementia due to any cause, or any other psychotic illness • History of suicide attempts or suicidal ideation in the past year • Active, major depression or generalized
Age minimum:
Age maximum:
Gender:
Female: yes Male: yes
|
Health Condition(s) or Problem(s) studied
|
Neuropathic Pain in Diabetic Peripheral Neuropathy MedDRA version: 9.1
Level: LLT
Classification code 10054095
Term: Neuropathic pain
|
Intervention(s)
|
Product Name: Carisbamate Product Code: RWJ-333369 Pharmaceutical Form: Tablet Current Sponsor code: RWJ-333369 Other descriptive name: Casrisbamate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use
Product Name: Carisbamate Product Code: RWJ-333369 Pharmaceutical Form: Tablet Current Sponsor code: RWJ-333369 Other descriptive name: Casrisbamate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 400- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use
Trade Name: Lyrica Product Name: Pregabalin Pharmaceutical Form: Capsule* Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 75- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use
Trade Name: Lyrica Product Name: Pregabalin Pharmaceutical Form: Capsule* Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use
|
Primary Outcome(s)
|
Primary end point(s): The primary efficacy endpoint is the mean of the last 7 Daily Average DPN Pain scores of the double-blind treatment phase on days study drug is taken.
|
Secondary Objective: • To evaluate the impact of 800 and 1,200 mg/day of carisbamate on: – Pain symptoms – Functional health status (including physical and social functioning) and well-being – Rescue medication use – Sleep interference • To evaluate global assessments of improvement and severity from subject perspective • To characterize the population pharmacokinetics of carisbamate in subjects with DPN • To evaluate long-term safety of carisbamate in subjects with DPN
|
Main Objective: The primary objective is to evaluate the efficacy, safety, and tolerability of 800 and 1,200 mg/day of carisbamate compared with placebo in reducing the average daily pain in subjects with diabetic peripheral neuropathy (DPN).
|
Secondary ID(s)
|
2008-008753-33-NL
|
CARISNPP2003
|
Source(s) of Monetary Support
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|